HC Wainwright Reiterates Buy Rating for FibroGen (NASDAQ:FGEN)

HC Wainwright reissued their buy rating on shares of FibroGen (NASDAQ:FGEN) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. StockNews.com assumed coverage on shares of FibroGen in a report on Thursday, February 13th. They issued a “hold” rating on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Trading Down 8.6 %

Shares of FibroGen stock opened at $0.71 on Thursday. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.80. The company has a market cap of $71.13 million, a price-to-earnings ratio of -0.57 and a beta of 0.75. The company’s 50-day moving average price is $0.53 and its 200-day moving average price is $0.43.

Institutional Investors Weigh In On FibroGen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new stake in FibroGen in the fourth quarter valued at approximately $27,000. Velan Capital Investment Management LP purchased a new stake in FibroGen in the fourth quarter valued at approximately $42,000. XTX Topco Ltd raised its stake in FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 77,693 shares in the last quarter. Franklin Street Advisors Inc. NC raised its stake in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 100,000 shares in the last quarter. Finally, FMR LLC raised its stake in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares in the last quarter. 72.71% of the stock is owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.